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Abstract
Background: Emphysema and chronic obstructive pulmonary disease (COPD) are well known independent risk
factors for lung cancer. However, the developmental mechanisms between emphysema/COPD and lung cancer
remain unknown. The purpose of this study was to evaluate PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in
squamous cell carcinoma (SCC) associated with emphysema/COPD.
Methods: A total of 59 patients with squamous cell lung carcinoma (SCC) resected between 2008 and 2012 were
retrospectively reviewed. Emphysema was assessed according to the Goddard score. Total severity was divided into
none-mild (0–7), moderate (8–15), and severe (≥ 16). Local severity around the existing tumor was divided into no
emphysema (0) and presence of emphysema (1–4). COPD severity was based on the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria. PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression were evaluated by
immunohistochemistry (IHC). Expression level was classified as tumor cells (TC) 3 (≥ 50%), TC2 (5–49%), TC1 (1–4%),
or TC0 (< 1%), and as tumor-infiltrating immune cells (IC) 3 (≥ 50%), IC2 (5–49%), IC1 (1–4%), or IC0 (< 1%) for PD-
L1. Expression level was compared between none-mild/moderate-severe total emphysema, no/presence of local
emphysema, no COPD/COPD, and GOLD 1/GOLD 2, 3.
Results: PD-L1 expression was significantly correlated with severity of emphysema in TC0, 1, 2 vs. TC3 (P = 0.012).
PD-L1 was significantly higher inversely in none-mild emphysema compared to moderate-severe (95% CI, 0.061–5.852,
P = 0.045). There were no other significant associations between PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression and
total/local severity of emphysema or presence of COPD/GOLD stage.
Conclusions: PD-L1 expression in SCC was correlated with severity of emphysema in TC0, 1, 2 vs. TC3 and more
frequent in none-mild emphysema than moderate-severe emphysema.
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Background
Lung cancer is the primary cause of cancer-related
death worldwide. It is well known that smoking is a
major risk factor for lung cancer [1]. Smoking causes
emphysema and chronic obstructive pulmonary di-
sease (COPD) [2, 3]. Several studies have found that
emphysema and COPD are independent risk factors
for lung cancer [4–6], especially squamous cell lung
carcinoma (SCC) [7, 8].
The efficacy of immune checkpoint inhibitors has been
established for SCC that express programmed death ligand
1 (PD-L1) [9, 10]. Although targeted therapy against adeno-
carcinoma with epidermal growth factor receptor (EGFR)
gene mutation or anaplastic lymphoma kinase (ALK) and
ROS1 proto-oncogene receptor tyrosine kinase (ROS1)
rearrangements have shown dramatic effects [11–13], few
targeted therapies against SCC have been identified. Previ-
ous reports have suggested that potential targets for therapy
against SCC including fibroblast growth factor receptor 1
(FGFR1), phosphatidylinositol - 4,5 - bisphosphate 3 - kin-
ase catalytic subunit alpha (PIK3CA), phosphatase and
tensin homolog (PTEN), and p16 [14–17].
The genetic causes of emphysema and COPD are
largely unknown [18, 19]. Furthermore, the developmen-
tal pathway between COPD and non-small cell lung can-
cer (NSCLC) remains elusive [20–22]. The purpose of
this study was to evaluate PD-L1, FGFR1, PIK3CA,




This was a retrospective study approved by the institu-
tional review board (Date of approval: Dec 27, 2012,
approval number: 2693) of Tokyo Women’s Medical
University Hospital. Written informed consent was
obtained from all patients before tumors were resected
and additional consent was waived.
Patients population and samples
This study included 59 patients who underwent surgery
for SCC between February 2008 and December 2012 at
Tokyo Women’s Medical University, Yachiyo Medical
Center. All patients had computerized tomography (CT)
and respiratory function tests to assess the suspected
malignancy and determine eligibility for surgical inter-
vention prior to surgery. Resected tumors were immedi-
ately fixed with 10% formalin, stained with hematoxylin
and eosin (HE) and prepared for immunohistochemistry
(IHC) staining.
Definition of emphysema
The severity of emphysema on CT was visually assessed
by two independent pulmonologists according to the
Goddard scoring system [23, 24]. Low attenuation area
(LAA) on six images of three lung slices (the right and left
lungs were evaluated separately) were analyzed for each
patient [25]. Each image was scored as follows: score 0 (no
LAA), score 1 (LAA of 1–25%), score 2 (LAA of 26–50%),
score 3 (LAA of 51–75%), and score 4 (LAA of ≥76%) [23].
Total severity score was categorized into one of three
groups as follows: none-mild (0–7), moderate (8–15),
and severe (≥ 16). Local severity score around the
tumor was classified as no-emphysema (0) and presence
of emphysema (1–4).
Definition of COPD
Respiratory function tests were performed to assess the
eligibility for surgery. Diagnosis of COPD was based on
the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) criteria after confirming the presence of
persistent airflow limitation by a post-bronchodilator
forced expiratory volume in one second (FEV1)/forced
vital capacity (FVC) < 70% [26]. The severity of air flow
limitation was classified using the GOLD staging
criteria with % predicted FEV1, as follows: GOLD 1
(≥ 80%), GOLD 2 (50–79%), GOLD 3 (30–49%), and
GOLD 4 (< 30%) [26].
Molecular and IHC analysis
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression was
evaluated by IHC staining of archived resected samples.
IHC was performed with the following antibodies: PD-
L1 (clone SP-142, diluted 1:100; Ventana Medical
System, Arizona, USA), FGFR-1 (polyclonal, diluted 1:
400; Abcam, Cambridge, UK), PIK3CA (Recombinant,
diluted 1:400; Abcam), PTEN (clone 138G6, diluted 1:
200; Cell Signaling, Massachusetts, USA), and p16
(Recombinant, diluted 1:2000; Abcam).
To improve the expression, the tissues were pre-
treated with microwaves in ethylenediaminetetraacetic
acid for PD-L1, or in retrieval solution (DAKO Target
Retrieval Solution pH 9, Glostrup, Denmark) for FGFR1
in citrate buffer for PTEN and p16, before staining.
Positive controls in IHC protocols were specimens
from pulmonary SCC where the target molecules have
been confirmed to be positive. To validate the speci-
ficity of the secondary antibody, negative reaction
control sections obtained by omission of the primary
antibody were used. IHC expression was evaluated by
one experienced pathologist and pulmonologist in a
blinded fashion. Each expression of tumor cells was
classified by staining as follows: tumor cells (TC) 3
(≥ 50%), TC2 (5–49%), TC1 (1–4%), and TC0 (< 1%)
[27]. Furthermore, tumor-infiltrating immune cells
were also evaluated for PD-L1 as follows: immune cells
(IC) 3 (≥ 50%), IC2 (5–49%), IC1 (1–4%), and IC0 (< 1%).
Immune cells were evaluated only for PD-L1, based on a
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previous study [27]. If the score did not initially agree be-
tween evaluators, a discussion was initiated. Analysis of
PD-L1 expression was as follows: TC0 vs. TC1, 2, 3, TC0,
1 vs. TC 2, 3, TC0, 1, 2 vs. TC3 and IC0 vs. IC1, 2, 3,
IC0, 1 vs. IC 2, 3, IC0, 1, 2 vs. IC3. Analysis of FGFR1,
PIK3CA, PTEN, and p16 expression was as follows:
TC0 vs TC1, 2, 3.
Data analysis
Each expression of IHC was compared between none-mild
(0–7) and mild-severe (8–24) emphysema groups of total
Goddard scoring, no-emphysema (0) and presence of em-
physema (1–4) tumor area groups, non-COPD and COPD
groups, and GOLD 1 and GOLD 2, 3 groups. Data ana-
lysis was carried out using Statistical Analysis System
(SAS institute, Cary, NC) and Graph Pad PRISM (Graph-
Pad Software, La Jolla, CA). P values < 0.05 were regarded
as statistically significant. The t-test was used to compare
between each expression and Goddard score. Chi-squared
test was used to compare between each expression
and severity of emphysema, presence of COPD/Gold
staging. Groups were compared using 95% confidence
intervals (CI).
Results
Baseline characteristics and molecular classification by
staining
A total of 59 patients with surgically resected SCC were
eligible for this study. Patient baseline characteristics
included sex, median age, smoking history, histology,
pathological stage, total severity of emphysema, local
severity of emphysema, presence of COPD, and GOLD
stage (Table 1). There were no significant differences
between total emphysema status, local emphysema
status, COPD status and GOLD stage based on sex,
smoking history and stage (Table 2). Classifications of
TC0–3, IC0–3 for PD-L1 (Fig. 1) and of TC0–3 for
FGFR1, PIK3CA, PTEN, and p16 expression were
recorded (Table 3).
Comparison between each classification of expression
and severity of emphysema
IHC expression of each molecular antibody was com-
pared to total/local severity of emphysema (Table 4).
PD-L1 expression was significantly correlated with total
severity of emphysema in TC0, 1, 2 vs. TC3 (P = 0.012).
However, there was no other significant association
between classification of expression and total/local
severity of emphysema. Since there was significant asso-
ciation in total severity of emphysema, the results be-
tween TC0, 1, 2 (PD-L1 0–49) and TC3 (PD-L1 50–100)
for total severity of emphysema were compared. There
was significant difference between groups (95% CI:
0.061–5.852, P = 0.045) (Fig. 2).
Comparison between each classification of expression
and presence of COPD/ GOLD stage
The results of each classification of expression and pre-
sence of COPD/Gold stage was compared (Table 4).
There was no significant association between classifica-
tion of expression and presence of COPD/GOLD stage.
Discussion
Few reports have investigated the associations be-
tween TC, PD-L1, emphysema, mutational analysis,
and COPD in NSCLC [28, 29]. One study on lung
adenocarcinoma found that patients with emphysema
had more PD-L1 positive cells than patients without
Table 1 Patient characteristics
Patient Characteristics No (%)
Patients 59







Median pack year (range) 58.9 (0–184)
Histology




















COPD chronic obstructive pulmonary disease, GOLD Global Initiative for
Chronic Obstructive Lung Disease
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emphysema [28]. Another study on NSCLC showed
that PIK3CA expression was significantly associated
with COPD [29].
In this study, PD-L1 expression was significantly
correlated with severity of total emphysema in TC0, 1, 2
vs. TC3 (P = 0.012). Furthermore, there was a significant
difference inversely in total severity of emphysema be-
tween TC0, 1, 2 (PD-L1 0–49) and TC3 (PD-L1 50–100)
(95% CI: 0.061–5.852, P = 0.045). There were no other
significant associations between classification of expres-
sion and total/local severity of emphysema, and between
classification of expression and presence of COPD/
GOLD stage. These results differ from previous studies
on the associations between PD-L1 expression and
emphysema in patients with lung adenocarcinoma [28],
and between PIK3CA gene mutation and COPD in
patients with NSCLC [29]. One explanation for this dis-
crepancy is that our study focused on SCC while other
studies focused on lung adenocarcinoma or NSCLC.
Another is that our study focused on protein expression
while other study focused on the gene mutation. These
differences may have influenced the results and may
Fig. 1 Representative image of PD-L1 expression for each staining level (10X). A TC0 and IC0 (< 1%), B TC1 and IC1 (1–4%), C TC2 and IC2 (5–49%), D
TC3 and IC3 (50–100%). PD-L1 programmed death ligand 1, TC tumor cells, IC immune cell















Male 33 17 0.78 18 32 0.54 26 24 0.59 34 16 0.14
Female 7 2 5 4 3 6 3 6
Smoking
Never 2 0 0.61 2 0 0.2 2 0 0.34 2 0 0.54
Ever 38 19 21 36 27 30 35 22
Stage
I 27 11 0.63 16 22 0.84 21 17 0.62 28 10 0.17
II 10 6 5 11 7 9 7 9
III 3 1 2 2 1 3 2 2
recurrence 0 1 0 1 0 1 0 1
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Table 4 Comparison between each classification of expression and severity of emphysema, presence of COPD, GOLD staging
Total severity of emphysema Local severity of emphysema Presence of COPD Staging of GOLD
Classify of expression none-mild moderate-severe P value none present P value No COPD COPD P value GOLD1 GOLD2,3 P value
PD-L1
TC0 6 1 0.28 5 2 0.06 3 4 0.72 5 2 0.61
TC1,2,3 34 18 18 34 26 26 32 20
TC0,1 14 5 0.5 9 10 0.36 7 12 0.19 11 8 0.6
TC2,3 26 14 14 26 22 18 26 14
TC0,1,2 20 16 0.012 13 23 0.57 17 19 0.71 22 14 0.75
TC3 20 3 10 13 12 11 15 8
IC0 1 0 0.49 1 0 0.2 0 1 0.32 1 0 0.44
IC1,2,3 39 19 22 36 29 29 36 22
IC0,1 2 0 0.32 2 0 0.07 0 2 0.16 2 0 0.27
IC2,3 38 19 21 36 29 28 35 22
IC0,1,2 20 7 0.34 14 13 0.06 16 11 0.15 18 9 0.56
IC3 20 12 9 23 13 19 19 13
FGFR1
TC0 17 9 0.72 8 18 0.25 13 13 0.91 14 12 0.21
TC1,2,3 23 10 15 18 16 17 23 10
PIK3CA
TC0 36 19 0.15 22 33 0.55 28 27 0.32 33 22 0.11
TC1,2,3 4 0 1 3 1 3 4 0
PTEN
TC0 23 12 0.68 17 18 0.07 16 19 0.52 20 15 0.29
TC1,2,3 17 7 6 18 13 11 17 7
p16
TC0 13 9 0.27 10 12 0.43 14 8 0.09 12 10 0.32
TC1,2,3 27 10 13 24 15 22 25 12
COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Chronic Obstructive Lung Disease, PD-L1 Programmed death ligand 1, TC
Tumor cells, IC Immune cells, FGFR1 Fibroblast growth factor receptor 1, PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha,
PTEN Phosphatase and tensin homolog
Table 3 Classification of each expression
Classify of expression (%) PD-L1 FGFR1 PIK3CA PTEN p16
TC0 7 (11.9) 26 (44.1) 55 (93.2) 35 (59.3) 22 (37.3)
TC1 12 (20.3) 15 (25.4) 3 (5.1) 8 (13.6) 19 (32.2)
TC2 17 (28.8) 17 (28.8) 1 (1.7) 15 (25.4) 16 (27.1)





PD-L1 programmed death ligand 1, FGFR1 fibroblast growth factor receptor 1, PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
alpha, PTEN phosphatase and tensin homolog, TC tumor cells, IC immune cell
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account for the differences in PD-L1 expression and
PIK3CA.
This study identified for the first time a significant as-
sociation between high expression of PD-L1 (≥ 50%) and
none-mild emphysema in SCC. However, the mecha-
nism behind this association remains unknown. Previous
studies have shown an increased proportion of PD-1
positive CD8 T-cells in the lungs of patients with COPD
lung such as lung emphysema. This appeared to con-
tribute to dysfunctional of CD8 T-cells [30, 31]. Our
findings suggest that tumor need not escape from CD8
T-cell attack, particularly given the low expression of
PD-L1 when emphysema is moderate-severe. On the
contrary, if a tumor escapes CD8 T-cell attack, it might
be attributed to high expression of PD-L1 in none-mild
emphysema.
This study found that none-mild emphysema was an
independent predictive factor of high PD-L1 expression
(≥ 50%). This result suggests the utility of non-invasive
ways of predicting high expression of PD-L1 (≥ 50%),
such as CT imaging. CT imaging may also be an effect-
ive way of deciding to use immune checkpoint inhibitors
[9, 10] in patients with SCC before determining PD-L1
expression with IHC. This might prevent significant life
threatening events associated with surgery and bron-
choscopy, such as decreasing respiratory function, em-
bolism, bleeding, and pneumothorax. In addition, this
might lead to insights regarding the mechanistic correl-
ation between PD-L1 expression and emphysema.
This study had several limitations. First, this was a
retrospective study performed at a single institution,
which may have influenced the results. A prospective
multicenter randomized control trial is needed to con-
firm our results. Second, although this study shows an
association between each expression and Goddard,
COPD, and GOLD stage, the associations between
those and overall survival rates remain unknown. An
evaluation of overall survival is needed. Third, although
LAA was evaluated with Goddard criteria, it is unclear
if the automated evaluation for LAA [32] would provide
the same results. Additional studies are needed to
determine what methods are most appropriate for
evaluating LAA.
Conclusion
In conclusion, there was a significant association between
TC0, 1, 2 vs. TC3 groups and none-mild vs. moderate-se-
vere emphysema groups in patients who underwent
surgical resection of lung SCC. PD-L1 expression was
significant higher in none-mild emphysema than in moder-
ate-severe emphysema. There was no significant association
between any other classification of expression for PD-L1,
FGFR1, PIK3CA, PTEN, p16 and total/local severity of em-
physema, between classification of expression for PD-L1,
FGFR1, PIK3CA, PTEN, p16 and presence of COPD/
GOLD staging. Further studies are needed to evaluate over-
all survival between classification of each expression and
total/local severity of emphysema, presence of COPD/
GOLD stage.
Abbreviations
COPD: Chronic obstructive pulmonary disease; GOLD: Global Initiative for
Chronic Obstructive Lung Disease; PD-L1: Programmed death ligand 1;
SCC: Squamous cell carcinoma
Fig. 2 Comparison between TC0, 1, 2 (PD-L1 0–49) and TC3 (PD-L1 50–100) based on Goddard score PD-L1 expression was more than 50% when
Goddard score was low (95% CI: 0.061–5.852, *P = 0.045). PD-L1 programmed death ligand 1
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